Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Fineline Cube Aug 13, 2026
Company Deals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Fineline Cube Aug 13, 2026
Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026
Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026
Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Fineline Cube Aug 13, 2026
Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Fineline Cube Aug 13, 2026
Company Drug

Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials

Fineline Cube Feb 22, 2023

China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...

Company Deals

Meihua International Partners with Hainan for Medical Tech Park and R&D Center

Fineline Cube Feb 22, 2023

Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has...

Company Deals

Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership

Fineline Cube Feb 22, 2023

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...

Drug Policy / Regulatory

CDE Releases 67th Batch of Chemical Generic Reference Preparations

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the 67th batch of chemical generic reference...

Drug

CDE Releases Guidelines for Chemically Synthesized Peptide Research

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Pharmaceutical Research of...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study

Fineline Cube Feb 21, 2023

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...

Company Deals

Abbott Partners with Sinopharm for Expanded Medical Solutions in China

Fineline Cube Feb 21, 2023

US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical...

Company Drug

Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment

Fineline Cube Feb 21, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has...

Company Drug

Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis

Fineline Cube Feb 21, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals Medical Device

We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface

Fineline Cube Feb 21, 2023

We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly...

Company Deals

Hybio Pharma and CR Medicine Collaborate on Market Expansion

Fineline Cube Feb 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot...

Company Drug

Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi

Fineline Cube Feb 21, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...

Company Drug

Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy

Fineline Cube Feb 21, 2023

Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...

Company Drug

Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023

Fineline Cube Feb 21, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...

Company Deals

Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D

Fineline Cube Feb 21, 2023

China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly...

Company Drug

Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China

Fineline Cube Feb 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment

Fineline Cube Feb 21, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...

Company R&D

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

Fineline Cube Feb 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...

Company Deals

Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development

Fineline Cube Feb 21, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership...

Company Drug

Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study

Fineline Cube Feb 20, 2023

Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...

Posts pagination

1 … 602 603 604 … 708

Recent updates

  • AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
  • Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease
  • Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China
  • IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform
  • Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Company Drug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.